SF3B1 and breast carcinoma: This observation is consistent with the hypothesized role of SF3B1 as a biomarker for immunotherapy currently under evaluation in a breast cancer clinical trial (44) but suggests that it may not generalize to additional cancer subtypes except for head and neck cancer.